What is TB-500?
A lab-made chain of 7 amino acids: a piece of the protein thymosin beta-4 (residues 17 to 23, LKKTETQ) with an acetyl group added at the start, not thymosin beta-4 itself.
US legal status
Open question
HHS's TB-500 policy is still the October 30, 2026 "draft": comments closed on November 13, 2026, and we found no final policy. Whether the file the notice names as its most current version, last changed November 9, 2026, changes TB-500's form, routes or conditions is not settled.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's search of FAERS, to March 26, 2025, found 0 reports. Its complaint system (HFCS, 2004 to March 2025) holds 2 complaints about TB-500 in blends with another peptide.6
- In FAERS (data to October 28, 2026), "TB-500" appears in 1 report, "TB500" in 0 and "thymosin beta-4" in 4 (form not stated). The one TB-500 report names a blend that contains TB-500, among other drugs, with the terms malignant lymphoid neoplasm, adverse drug reaction and product dispensed by unauthorized provider; it does not show that the blend caused them.15
- Every complaint the FDA reviewed, and the one openFDA report, involve blends.615
What the FDA has said
- The FDA's Category 2 page says the fragment "may pose risk for immunogenicity", an immune reaction, for some routes, because of aggregation and impurities. The FDA has no data on people exposed to it.5
- The FDA's briefing says TB-500 is "not physically and chemically well characterized", that a public certificate of analysis skipped the assay, impurity, endotoxin and aggregate tests, and that the FDA "cannot rule out the potential for immunogenicity". In general, injection under the skin carries more immunogenicity risk than injection into muscle or a vein, with outcomes up to "life-threatening and catastrophic reactions": a statement about peptides in general, not an event seen with TB-500.6
In studies and reviews
- A review of lab studies found higher levels of the full thymosin beta-4 protein in several metastatic tumors, linked with metastasis and blood-vessel growth signals. These are lab and tissue data, not TB-500.30
No data
Product quality
- The FDA found "multiple salts, and derivatives, including different active moieties" sold under the name TB-500.6
- Anti-doping labs confirmed the acetylated 17–23 fragment in products sold as TB-500. A French racing lab found online TB500 and TB1000 products "not systematically consistent" with their descriptions.212223
- The nominator's certificate of analysis allowed up to 1.0% of a single unidentified impurity.6
Compounded TB-500 is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
The conditions of the HHS policy
The policy covers a compounded product only when all of its conditions are met.
- 1.HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (10 conditions, Appendix A)Tier 1: regulator or registerHHSread Nov 16, 2026↩
- 2.Appendix B: Peptide Identities and JustificationsTier 1: regulator or registerHHSread Nov 16, 2026↩
- 3.FR Doc 2026-22192, 91 FR 68526–68527 (Oct 30, 2026)Tier 1: regulator or registerFederal Registerread Nov 16, 2026↩
- 4.Docket HHS-OASH-2026-0496Tier 1: regulator or registerRegulations.govread Nov 16, 2026↩
- 5.Certain bulk drug substances that may present significant safety risks (Apr 22, 2026)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 6.FDA briefing document: TB-500-related bulk drug substances, PCAC Jul 23–24, 2026Tier 1: regulator or registerFDA CDERread Nov 16, 2026↩
- 7.FDA briefing document: KPV-related bulk drug substances, PCAC Jul 23–24, 2026Tier 1: regulator or registerFDA CDERread Nov 16, 2026
- 8.PCAC questions, Jul 23–24, 2026Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 9.PCAC meeting page, Jul 23–24, 2026 (no minutes)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 10.Bulk-list bound? PCAC backs majority of peptides (Jul 27, 2026)Tier 3: reference, law firm or pressMcDermott Will & Schulteread Nov 16, 2026↩
- 11.PEPTIDE-L WAVE! PCAC approves four bulk drug substances (Jul 2026)Tier 3: reference, law firm or pressHyman Phelps (FDA Law Blog)read Nov 16, 2026↩
- 12.WADA Prohibited List 2026 (S2.3)Tier 1: regulator or registerWADAread Nov 16, 2026↩
- 13.Anthony McCauley accepts doping sanction (Sep 17, 2025)Tier 1: regulator or registerUSADAread Nov 16, 2026↩
- 14.Warning letter, Warrior Labz SARMS 655280 (Jun 12, 2023)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 15.openFDA FAERS queries: "TB-500", TB500, "thymosin beta-4" (data to Oct 28, 2026)Tier 1: regulator or registeropenFDAread Nov 16, 2026↩
- 16.openFDA Drugs@FDA query "TB-500" (no match)Tier 1: regulator or registeropenFDAread Nov 16, 2026↩
- 17.eCFR 21 CFR Part 1308 (2026-11-01)Tier 1: regulator or registereCFRread Nov 16, 2026↩
- 18.NCT07487363 (TBRIDGE-CV), re-read via API todayTier 1: regulator or registerClinicalTrials.govread Nov 16, 2026↩
- 19.ClinicalTrials.gov query.intr=thymosin beta-4 (18 studies)Tier 1: regulator or registerClinicalTrials.govread Nov 16, 2026↩
- 20.PubMed E-utilities counts for TB-500Tier 1: regulator or registerNIH NLMread Nov 16, 2026
- 21.Esposito S et al. Drug Test Anal 2012;4(9):733-8. PMID 22962027Tier 2: peer-reviewed or trial registryWileyread Nov 16, 2026↩
- 22.Ho EN et al. J Chromatogr A 2012;1265:57-69. PMID 23084823Tier 2: peer-reviewed or trial registryElsevierread Nov 16, 2026↩
- 23.Delcourt V et al. Drug Test Anal 2023;15(4):458-464. PMID 36482504Tier 2: peer-reviewed or trial registryWileyread Nov 16, 2026↩
- 24.Tham A et al. J Am Acad Orthop Surg 2026. PMID 42937313Tier 2: peer-reviewed or trial registryAAOSread Nov 16, 2026
- 25.Froum S et al. Front Oral Health 2026;7:1907109. PMID 42876687Tier 2: peer-reviewed or trial registryFrontiersread Nov 16, 2026↩
- 26.Biçer O et al. Jt Dis Relat Surg 2026;37(3):822-837. PMID 42542926Tier 2: peer-reviewed or trial registryJt Dis Relat Surgread Nov 16, 2026↩
- 27.Ruff D et al. Ann N Y Acad Sci 2010;1194:223-9. PMID 20536472 (abstract re-read today: 4 cohorts of 10, IV, 14 days)Tier 2: peer-reviewed or trial registryWileyread Nov 16, 2026
- 28.Wang X et al. J Cell Mol Med 2021;25(17):8222-8. PMID 34346165Tier 2: peer-reviewed or trial registryWileyread Nov 16, 2026
- 29.HHS issues interim enforcement discretion policy for compounding (Nov 4, 2026)Tier 3: reference, law firm or pressHolland & Knightread Nov 16, 2026↩
- 30.Xiao Y et al. Thymosin β4: a potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr 2012;22(2):109-16. PMID 22856429Tier 2: peer-reviewed or trial registryBegell Houseread Nov 16, 2026↩
- 31.Bulk drug substances used in compounding under section 503ATier 1: regulator or registerFDAread Nov 16, 2026↩
- 32.PubMed count: thymosin beta-4 AND neoplasms[mh] (164)Tier 1: regulator or registerNIH NLMread Nov 16, 2026
- 33.Warning letter, GenoGenix LLC, MARCS-CMS 718739 (Jan 20, 2026; posted Mar 3, 2026)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 34.FDA warning letters search: "TB-500", "TB500", "thymosin" (read 2026-11-16)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 35.Federal Register API searches: "TB-500", "thymosin", peptide compounding since 2026-10-30 (read 2026-11-16)Tier 1: regulator or registerFederal Registerread Nov 16, 2026↩
- 36.Bulk drug substances nominated for use in compounding under section 503A (Updated May 14, 2026)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 37.Bulk drug substances nominated for use in compounding under section 503B (Updated March 21, 2025)Tier 1: regulator or registerFDAread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.